It has been reported in several studies with solid proof that FOXP4-AS1 is overexpressed in hepatocellular carcinoma (17), esophageal squamous cell carcinoma (18), prostate cancer (19), nasopharyngeal carcinoma (20, 21), Ewing sarcoma (ES) (22), mantle cell lymphoma (MCL) (23), and osteosarcoma (24), where it promoted cancer progression and played an oncogenic role, and its upregulation usually predicts poor prognosis of these cancers. Here, FOXP4 is linked to hepatocellular carcinoma.